[go: up one dir, main page]

EA030564B9 - СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2 - Google Patents

СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2

Info

Publication number
EA030564B9
EA030564B9 EA201692550A EA201692550A EA030564B9 EA 030564 B9 EA030564 B9 EA 030564B9 EA 201692550 A EA201692550 A EA 201692550A EA 201692550 A EA201692550 A EA 201692550A EA 030564 B9 EA030564 B9 EA 030564B9
Authority
EA
Eurasian Patent Office
Prior art keywords
protein
tetrahydrospiro
indole
pyrrole
inhibitors
Prior art date
Application number
EA201692550A
Other languages
English (en)
Other versions
EA201692550A1 (ru
EA030564B1 (ru
Inventor
Марцин Федер
Ивона Калиновская
Иоанна Адриана Ящевская
Эва Бурхард
Войцех Левандовский
Уршула Бульковская
Мария Мазур
Катаржина Вос-Лятоси
Original Assignee
Адамед Сп. З О.О.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адамед Сп. З О.О. filed Critical Адамед Сп. З О.О.
Publication of EA201692550A1 publication Critical patent/EA201692550A1/ru
Publication of EA030564B1 publication Critical patent/EA030564B1/ru
Publication of EA030564B9 publication Critical patent/EA030564B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Спирооксоиндольное соединение, представленное формулой, выбранной из группы, состоящей из формулы (IA) и (IB), где все символы являются такими, как определено в настоящем описании. Соединение можно применять в способе предотвращения и/или лечения заболеваний, выбранных из группы, состоящей из рака, иммунных заболеваний, воспалительных состояний, аллергических кожных заболеваний, связанных с чрезмерной пролиферацией, и вирусных инфекций.
EA201692550A 2014-06-12 2015-06-11 СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2 EA030564B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL40854014 2014-06-12
PCT/IB2015/054425 WO2015189799A1 (en) 2014-06-12 2015-06-11 Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction

Publications (3)

Publication Number Publication Date
EA201692550A1 EA201692550A1 (ru) 2017-07-31
EA030564B1 EA030564B1 (ru) 2018-08-31
EA030564B9 true EA030564B9 (ru) 2019-02-28

Family

ID=54832985

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692550A EA030564B9 (ru) 2014-06-12 2015-06-11 СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2

Country Status (13)

Country Link
US (1) US20170129903A1 (ru)
EP (1) EP3154982B1 (ru)
JP (1) JP2017517555A (ru)
KR (1) KR20170012559A (ru)
CN (1) CN106795168A (ru)
AU (1) AU2015273106A1 (ru)
BR (1) BR112016028888A2 (ru)
CA (1) CA2947134A1 (ru)
EA (1) EA030564B9 (ru)
IL (1) IL248839A0 (ru)
MX (1) MX2016016363A (ru)
WO (1) WO2015189799A1 (ru)
ZA (1) ZA201700110B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CA3086001A1 (en) 2016-12-21 2018-06-28 Board Of Regents Of The University Of Nebraska Dimers of covalent nfkb inhibitors
JP2021508727A (ja) * 2017-12-29 2021-03-11 甘李薬業股▲フン▼有限公司Ｇａｎ＆Ｌｅｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ 腫瘍阻害剤として使用できる化合物およびその調製方法と応用
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN114057756B (zh) * 2021-12-10 2022-12-09 山东第一医科大学(山东省医学科学院) 一种抗肿瘤活性的吡咯烷基螺氧化吲哚类化合物及其合成方法
WO2024078370A1 (zh) * 2022-10-13 2024-04-18 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
CN119613416B (zh) * 2024-12-23 2025-11-04 聊城金歌合成材料有限公司 甲氧基螺吲哚吡咯烷酮化合物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916850B2 (en) 2001-05-03 2005-07-12 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
EP2005957B1 (en) 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
CL2007002953A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
JP5460324B2 (ja) 2006-10-12 2014-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド 治療剤としてのスピロ−オキシインドール化合物の使用
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
WO2012121361A1 (ja) 2011-03-10 2012-09-13 第一三共株式会社 ジスピロピロリジン誘導体
CN103717605B (zh) * 2011-05-11 2016-05-18 密执安州立大学董事会 螺-羟吲哚mdm2拮抗剂

Also Published As

Publication number Publication date
AU2015273106A1 (en) 2016-11-17
EP3154982B1 (en) 2018-05-02
CA2947134A1 (en) 2015-12-17
JP2017517555A (ja) 2017-06-29
KR20170012559A (ko) 2017-02-02
EA201692550A1 (ru) 2017-07-31
CN106795168A (zh) 2017-05-31
ZA201700110B (en) 2018-04-25
US20170129903A1 (en) 2017-05-11
MX2016016363A (es) 2017-04-06
BR112016028888A2 (pt) 2017-08-22
IL248839A0 (en) 2017-01-31
EA030564B1 (ru) 2018-08-31
EP3154982A1 (en) 2017-04-19
WO2015189799A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
EA030564B9 (ru) СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ СИСТЕМУ 1,1',2,5'-ТЕТРАГИДРОСПИРО[ИНДОЛ-3,2'-ПИРРОЛ]-2,5'-ДИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ p53-Mdm2
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
IL251285A0 (en) 3-substituted 5-amino-h6-triazolo[5,4-d]pyrimidine-7,2-dione compounds for the treatment and prevention of viral infection
IL264402B (en) History of pyrrolo(2,3–d)pyrimidine for the treatment of viral infections and other diseases
NZ712453A (en) Tricyclic heterocycles as bet protein inhibitors
GEP201706686B (en) Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
AU2015352440B2 (en) Compounds
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EA201500942A1 (ru) ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
IN2013MU03216A (ru)
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
WO2014176068A3 (en) Treatment and prevention of bacterial skin infections using oritavancin
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
HK1231077A1 (en) Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
UA66165U (ru) Применение витаминной композиции, которая содержит витамины С и К3, в качестве средства для лечения вирусных инфекций

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU